Results 81 to 90 of about 28,042 (215)
Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
BMC Nephrology, 2020 Background Peritoneal ultrafiltration (pUF) in refractory heart failure (HF) reduces the incidence of decompensation episodes, which is of particular significance as each episode incrementally adds to mortality.
Leonie Grossekettler +10 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Bar graphs showing the distribution of multimorbidity groups across regions and HFrEF/HFpEF.
, 2018 By region (A) and HFrEF versus HFpEF (B). AF, atrial fibrillation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
John J. V. McMurray (784980) +10 more
core +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
, 2018 Heart failure with reduced ejection fraction (HFrEF) is a deadly and disabling disease. A key derangement contributing to impaired exercise performance in HFrEF is decreased nitric oxide (NO) bioavailability.
Racette, Susan B. +3 more
core +1 more source
Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes [PDF]
, 2017 Purpose: The prevalence and consequences of prediabetic dysglycemia and undiagnosed diabetes is unknown in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and has not been compared to heart failure and reduced ejection ...
Søren L. Kristensen +27 more
core +1 more source
HFrEF pharmacological treatment: ACEIs and/or ARBs
, 2018 Several classes of inhibitors of the renin–angiotensin system were developed as antihypertensive agents. Following the early observations of favourable haemodynamic effects of angiotensin-converting enzyme inhibitors (ACEIs) in patients with congestive ...
Marc A. Pfeffer
core +1 more source
, 2022 Background: Heart failure with reduced ejection fraction (HFrEF) is a complex, chronic disease and is among the top causes of morbidity and mortality. Angiotensin receptor-neprilysin inhibitor drugs represented by sacubitril/valsartan are the key drugs ...
Qian Xiang (93550) +8 more
core +1 more source
Phenotyping patients with chronic obstructive pulmonary disease and heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher +12 more
wiley +1 more source